Pfizer’s COVID Pill Paxlovid Shows No Benefit In Younger Adults: Study

Paxlovid was approved by the FDA late last year for people and children 12 and older who are classified high risk. However, Pfizer's COVID pill paxlovid shows no benefit in younger adults, according to a study.

President Biden, First Lady Jill Biden, and Dr. Anthony Fauci all started to experience "rare" rebound instances after taking Pfizer's Covid-19 pill. According to the Washington Post, who cited an Israeli study that was released in the New England Journal of Medicine, Pfizer's Covid-19 pill offers "little or no benefit for younger adults."

The results from a 109,000-patient Israeli study are likely to renew questions about the U.S. government’s use of Paxlovid, which has become the go-to treatment for COVID-19 due to its at-home convenience. The Biden administration has spent more than $10 billion purchasing the drug and making it available at thousands of pharmacies through its test-and-treat initiative.

Researchers discovered that although the medication, when ta...

Limited Time

Full Access

$10
Monthly

Included:

  • Access to All Articles.
  • One Plan. No Tiers.
  • No Ads.
  • Cancel anytime.
register now

 
Do you have a tip or sensitive material to share with GGI? Are you a journalist, researcher or independent blogger and want to write for us? You can reach us at [email protected].